Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Difference
    0.3%
    Check dated 2025-05-08T13:48:13.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.6%
    Check dated 2025-05-01T06:14:45.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2025-04-24T00:13:25.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed information about a Phase II study involving pembrolizumab for treating relapsed or refractory lymphomas, while adding new collaborators and a revision update.
    Difference
    34%
    Check dated 2025-04-16T20:25:51.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.3%
    Check dated 2025-04-09T13:24:36.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-02T00:06:47.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.